Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain
RodrÃguez López, Manuel, MegÃas Vericat, Juan Eduardo, Albo López, Carmen, Bonanad, SantiagoVolume:
13
Journal:
BMJ Case Reports
DOI:
10.1136/bcr-2019-234142
Date:
October, 2020
Fichier:
PDF, 423 KB
2020